Together, these data identify <i>CDK12</i> as a <i>bona fide</i> tumor suppressor gene with impact on tumor progression and lends support to paralog-based synthetic lethality as a promising strategy for treating <i>CDK12-</i>mutant mCRPC. Here, CDK12 is linked to neoplasm.